The rapid invention of genome-editing technologies over the past decade, which has already been transformative for biomedical research, has raised the tantalizing prospect of an entirely new therapeutic modality. Whereas the treatment of chronic cardiovascular diseases has heretofore entailed the use of chronic therapies that typically must be taken repeatedly and frequently for the remainder of the lifetime, genome editing will enable the development of “one-and-done” therapies with durable effects. This Review summarizes the variety of available genome-editing approaches, including nuclease editing, base editing, epigenome editing, and prime editing; illustrates how these various approaches could be implemented as novel therapies for cardiovascular diseases; and outlines a path from technology development to preclinical studies to clinical trials. Although this Review focuses on PCSK9 as an instructive example of the various genome-editing approaches under active investigation, the lessons learned will be broadly applicable to the treatment of a variety of diseases.
Moving toward genome-editing therapies for cardiovascular diseases

Kiran Musunuru1,2,3

1Cardiovascular Institute, 2Department of Medicine, and 3Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

The rapid invention of genome-editing technologies over the past decade, which has already been transformative for biomedical research, has raised the tantalizing prospect of an entirely new therapeutic modality. Whereas the treatment of chronic cardiovascular diseases has heretofore entailed the use of chronic therapies that typically must be taken repeatedly and frequently for the remainder of the lifetime, genome editing will enable the development of “one-and-done” therapies with durable effects. This Review summarizes the variety of available genome-editing approaches, including nuclease editing, base editing, epigenome editing, and prime editing; illustrates how these various approaches could be implemented as novel therapies for cardiovascular diseases; and outlines a path from technology development to preclinical studies to clinical trials. Although this Review focuses on PCSK9 as an instructive example of the various genome-editing approaches under active investigation, the lessons learned will be broadly applicable to the treatment of a variety of diseases.

Introduction

Genome editing holds the potential to revolutionize the treatment of chronic cardiovascular diseases, such as coronary heart disease. Whereas all existing pharmacological treatments for coronary heart disease require taking pills daily or receiving injections every few weeks to months — for the rest of the lifetime, in order to accrue the full therapeutic benefit — genome editing results in permanent changes at the DNA level and offers the possibility of “one-and-done” therapies that would confer long-lasting protection against disease. Such therapies would have the dual advantages of maximizing the therapeutic effect (no missed doses) and eliminating a lack of medication adherence (an extremely common phenomenon) as an obstacle to health. The last few years have seen a wealth of promising data that point the way to a future in which many patients will benefit from genome-editing therapies. Besides outlining the varied genome-editing approaches that are now available for use, this Review focuses on the gene for which, by far, the most proof-of-concept studies have been reported — PCSK9, a regulator of blood cholesterol levels and driver of coronary heart disease risk — with the goal of illustrating for the reader the various ways in which the field is advancing the development of genome-editing therapies for cardiovascular diseases.

Genome-editing approaches

Any discussion of genome-editing therapies should begin with a description of the variety of editing tools now available for use. The first generation of tools, collectively known as engineered nucleases, have two types of functionality: the ability to search for and specifically bind to a target genomic sequence, and the ability to generate a double-strand DNA break within that sequence. Newer tools have emerged from separating the two types of functionality and pairing the search-and-bind ability with any of a variety of gene-modifying activities: chemical modification of DNA bases (base editing), modification of gene expression (epigenome editing), and reverse transcription to introduce new DNA sequences copied from RNA templates (prime editing). Each of these approaches is briefly described in the following sections; a more comprehensive discussion of genome-editing tools and their research and clinical applications, along with a complete set of references (which the need for brevity precludes from including in this Review), is available elsewhere (1).

Nuclease editing. There are four major types of engineered nucleases: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems. Each has the ability to seek out specific genomic sequences and to introduce double-strand DNA breaks, although the mechanisms by which they carry out these tasks are quite different. This Review will focus primarily on the CRISPR/Cas systems, as they are the most widely used class of nucleases and have the best prospects for translation into cardiovascular therapies in the near future.

The CRISPR/Cas systems of bacterial origin that are widely used for genome editing — CRISPR/Cas9 and CRISPR/Cas12 — each have two components, a Cas protein and a guide RNA (2). The guide RNA provides the search-and-bind ability, encoded within the RNA sequence itself, whereas the Cas protein has the ability to produce a double-strand break, employing either one or two cleavage domains to cut the two DNA strands. Streptococcus pyogenes Cas9, or SpCas9, was the first CRISPR/Cas system to be adapted...
The ultimate outcomes of nuclease editing depend on each cell’s attempt to repair the nuclease-induced double-strand break. The default repair mechanism is non-homologous end joining (NHEJ), whereby the free DNA ends are ligated together, which can restore the original DNA sequence or introduce insertions or deletions. This strategy is suitable for disrupting genes or non-coding elements in the genome. HDR enables more precise changes but requires the addition of a template, which reduces its efficiency. Adapted with permission from the Journal of the American College of Cardiology (58).
chromosomal abnormalities; and off-target editing, due to the nuclease having the potential to bind to sites that are an imperfect match to the guide RNA spacer, resulting in indel mutations at sites other than the intended target site. In theory, if an off-target edit were to occur in a tumor suppressor gene or oncogene, it could confer an increased long-term risk of cancer. Alterations of either the Cas protein or the guide RNA can reduce off-target editing, though often at the cost of reduced on-target editing (18-20).

**Base editing.** Base editing (as well as epigenome editing and prime editing) takes advantage of the fact that CRISPR/Cas9 can be directed to a desired site in the genome even if the Cas9 cleavage domains are altered such that it can only cut one DNA strand (nicking Cas9, or nCas9) or neither DNA strand (dead Cas9, or dCas9). Fusion of additional domains to the nCas9 or dCas9 protein can add different types of functionality to the CRISPR/Cas9 system.

There are two major classes of base editors, cytosine base editors that can cause C on a DNA strand to be replaced by another base (typically T, though in some cases G) (21, 22) and adenine base editors that can cause A to be replaced by G (23) (Figure 2). If nCas9 is fused to any of a variety of naturally occurring cytidine deaminase domains (e.g., from the APOBEC1 protein or the AID protein), the deaminase can potentially act upon any C within an editing window on the non-target DNA strand. (The unwinding of the DNA strands by Cas9 and hybridization of the target strand to the guide RNA create a structure known as an R-loop, which makes a portion of the non-hybridized, non-target strand into a single-strand DNA bubble that is accessible to action by the deaminase domain — thus defining the editing window, the extent of which varies depending on the specific Cas9 ortholog used.) Deamination converts C to U (uracil), which ordinarily would be restored back to C by the action of uracil-DNA glycosylase; fusion of yet another domain to nCas9, an inhibitor of uracil-DNA glycosylase, prevents this repair. nCas9 nicks only the target strand; nick repair entails removal of nucleotides around the site of the nick, followed by replacement of the nucleotides via complementarity to the non-target strand. For any U present in the non-target strand, an A goes into the complementary position in the target strand (since A and U can form a base pair). Following nick repair, the cell eventually replaces the non-standard U (normally found only in RNA) with the standard T. In this way, a C-G base pair is edited to a T-A base pair.

Because there is no naturally occurring adenosine deaminase that acts on single-strand DNA, protein evolution was used in the laboratory to create a novel DNA deaminase (23). Fusion of this evolved deaminase domain to nCas9 enables adenine base editing, which operates similarly to cytosine base editing. Within the editing window on the non-target strand, A is converted to I (inosine), nick repair occurs on the target strand, an A goes into the target strand opposite the I, and eventually the non-standard I is replaced with the standard G. Thus, an A-T base pair is edited to a G-C base pair.

**Epigenome editing.** If dCas9 is directed to a sequence in a gene promoter or transcriptional enhancer, it has the potential to sterically interfere with factors that normally interact with that sequence (24). Called CRISPR interference — by analogy to RNA interference
mediated by short hairpin RNAs, though quite different in mechanism — this phenomenon can be exploited to knock down the expression of specific genes. CRISPR interference is more potent if dCas9 is fused to a domain, such as the KRAB (Krüppel-associated box) domain, that actively represses gene expression by modifying the local chromatin structure (Figure 2 and ref. 25). The opposite phenomenon, called CRISPR activation, is achieved either by fusing domains that enhance gene expression (such as the transcriptional activator VP16) to dCas9 or by extending the sequence of the guide RNA on its 3′ end with RNA aptamers that recruit activation domains (Figure 2 and ref. 26). With either CRISPR interference or CRISPR activation, no change is made to the DNA sequence, and the gene expression effect appears to endure only as long as the editing protein is present, i.e., the effect is transient.

A distinct type of epigenome editing involves alteration of the methylation state of DNA sequences, particularly at cytosine bases in CpG dinucleotide sequences. Methylation near the transcription start site typically is linked to gene silencing, whereas non-methylation is linked to gene activation. Fusions of methyltransferase or demethylase domains to dCas9 can decrease or increase gene expression, respectively, and the methylation changes can endure long-term while still being reversible if an epigenome editor with the opposite effect is later applied to the same genomic site (27).

Other types of editing. Prime editing was recently developed with the goal of overcoming the limitations in the types of changes that can be made by base editing, as well as the limitations of HDR (28). nCas9 is fused to a reverse transcriptase that can build a DNA strand complementary to a single-strand RNA substrate. The substrate is provided by an extension of the guide RNA on its 3′ end, with an RNA sequence that is complementary to the non-target DNA strand but also includes a desired mutation. (The extended guide RNA is referred to as pegRNA.) nCas9 nicks the non-target strand, and the 3′ end of the pegRNA hybridizes with the non-target strand on one side of the nick (5′ direction), which forms an RNA-DNA duplex that serves as a template for reverse transcriptase, which in turn builds a DNA sequence with the desired mutation on the middle portion of the pegRNA (Figure 3). This new DNA strand can replace part of the non-target strand, resulting in permanent incorporation of the mutation. Although its efficiency remains lower than that of nuclease NHEJ editing or base editing (albeit higher than that of HDR editing), prime editing can precisely introduce a wide variety of mutations: single-nucleotide changes of any kind, and indel mutations of various sizes up to dozens of base pairs in length and potentially even longer. The extent of off-target editing with prime editors remains to be defined.

RNA editing is an orthogonal editing approach that uses the Cas13 family of proteins (29). Like CRISPR/Cas9 and CRISPR/Cas12, CRISPR/Cas13 systems have protein and RNA components, but they act on target RNAs rather than target DNAs. RNA editors can be used either to degrade target RNAs (29) or to make base edits (A-to-I edits or C-to-U edits) in target RNAs (30, 31). Because RNA molecules are short-lived, the persistence of the RNA effects depend on the prolonged presence of the RNA editor so that it continues to act on any newly transcribed RNA molecules.

Therapeutic genome editing: the example of PCSK9
For cardiovascular diseases, virtually all therapeutic genome-editing applications that are under active exploration would take place within the bodies of patients, in organs like the heart and liver — in vivo applications — rather than in cells taken from the body, with the editing occurring outside the body, and then transplanted back into the body — ex vivo applications. Many of the proof-of-concept studies for in vivo therapeutic genome editing have focused on genes closely tied to a well-established, modifiable causal risk factor for atherosclerotic cardiovascular disease, namely low-density lipoprotein cholesterol (LDL-C). One gene in particular stands out: the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene. Because this gene is preferentially expressed in the hepatocytes in the liver, and its protein product is secreted into the bloodstream, where it exerts its primary effect of increasing the blood LDL-C concentration, it has emerged as a popular target gene against which to test out new genome-editing technologies. The liver is an eminently targetable organ through a variety of delivery methods, and both the blood PCSK9 protein level and the blood LDL-C level represent easily measured pharmacodynamic markers of PCSK9 gene editing. As such, concentrating this Review’s discussion on published PCSK9 editing studies provides a comprehensive overview of progress in the therapeutic genome editing field and illustrates the key choices that must be made in designing genome-editing therapies, with no other genes (whether involved in cardiovascular diseases or in other diseases) having nearly the same breadth of data at the present time.


Furthermore, a few individuals with complete knockout of PCSK9 without having any serious adverse health consequences (34). As well as up to 88% reduction in risk of coronary heart disease function) mutations have substantially reduced blood LDL-C levels whereas people with single copies of gain-of-function mutations in the gene (32), specifically elevated blood LDL-C levels) via patients who were found to have single copies of PCSK9 nonsense (loss-of-function) mutations have been reported (35, 36). These observations have made PCSK9 a compelling drug target for the treatment and prevention of coronary heart disease, with three PCSK9-targeting drugs already approved for use in patients — alirocumab (a monoclonal antibody that binds PCSK9 protein in the blood), evolocumab (a monoclonal antibody that binds PCSK9 protein in the blood), and inclisiran (a small interfering RNA that knocks down PCSK9 mRNA levels in hepatocytes) — and a number of others in the drug development pipeline.

In an early demonstration of high-efficiency in vivo mammalian genome editing, an adeno viral vector, comprising a DNA core that encoded SpCas9 and a guide RNA targeting a sequence in exon 1 of the mouse Pcsk9 gene, was used to knock down Pcsk9 in the mouse liver by introducing loss-of-function mutations via NHEJ (37). Adenoviral vectors are generally avoided for use in patients because of the risk of severe and potentially life-threatening immune responses to the vectors; adeno-associated viral (AAV) vectors are preferred because they are better tolerated immunologically and thus more appropriate for clinical use. One disadvantage of AAV vectors is their limited cargo capacity (<5 kb of exogenous sequence) in which most genome-editing tools do not fit. For example, genetically encoded SpCas9 is about 4.2 kb, and a guide RNA expression cassette is about 500 base pairs, leaving minimal room for a promoter sequence to express SpCas9 and a polyadenylation sequence. With their much larger cargo capacity, adenoviral vectors were chosen for this initial proof-of-concept study of in vivo genome editing by CRISPR/Cas9. The investigators administered the SpCas9 vector or a control vector to wild-type mice. After several days, there was more than 50% whole-liver editing at the Pcsk9 target site; the most common edits were 1- or 2-base pair deletions or insertions, with edits as large as dozens of base pairs occurring with much less frequency. The Pcsk9 editing was accompanied by reductions of blood PCSK9 protein levels of about 90% and of blood cholesterol levels of 35%–40%, almost as much as the 36%–52% reductions of cholesterol observed in germline Pcsk9-knockout mice (38). This initial study showed no evidence of editing at a handful of candidate off-target sites.

In a subsequent study, a different group of investigators replicated the same editing results in mice treated with a similar adenoviral vector with SpCas9 and the same Pcsk9 guide RNA (39). The investigators rigorously assessed for off-target editing in the liver via a two-stage strategy. They first screened for candidate off-target sites using a biochemical technique called CIRCLE-Seq, in which circularized mouse genomic DNA fragments were mixed with SpCas9 protein and the Pcsk9 guide RNA in vitro, followed by next-generation sequencing to identify linearized DNA fragments. This procedure yielded a list of 182 candidate sites. In the second stage, the investigators performed PCR amplification of the candidate sites and deep next-generation sequencing of the amplicons from liver genomic DNA samples from the SpCas9-treated mice. They observed no editing at any of the sites, suggesting that it is possible to select genome-editing reagents with enough editing specificity that there is no detectable off-target mutagenesis in vivo.

Despite the encouraging results of these studies, they have no direct relevance to what might happen with PCSK9 editing in human patients, in light of three major differences between mice and humans. First, there are substantial differences between the mouse Pcsk9 and human PCSK9 gene sequences, such that it is prohibitive to identify an effective guide RNA matching both species. Second, there are substantial differences between the mouse and human genomes, such that off-target profiling of the mouse genome would not be predictive of off-target editing in the human genome. Third, there are substantial physiological differences between mouse and human hepatocytes, such that gene editing outcomes could differ significantly between the two cell types.

For a more relevant assessment of efficacy and safety of a potential human PCSK9-editing therapy than can be achieved in wild-type mice, a study was undertaken in chimeric liver-humanized mice, a model system in which the endogenous mouse hepatocytes are replaced with transplanted human hepatocytes (40). Liver-humanized mice were treated with an adenoviral vector encoding SpCas9 and a guide RNA targeting a sequence in exon 1 of the human PCSK9 gene. There was about 50% NHEJ-mediated editing of the human PCSK9 alleles present in the humanized liver, with no editing observed at a handful of candidate off-target sites, along with about 50% reduction of human PCSK9 protein levels in the blood.

The next set of studies pivoted away from adenoviral vectors to delivery approaches more amenable to clinical use. In the first study to use AAV to achieve high-efficiency in vivo mammalian genome editing, SaCas9 along with either of two guide RNAs targeting sequences in the mouse Pcsk9 gene was encoded in a single AAV vector (9). Either AAV vector, upon administration to wild-type mice, achieved 40%–50% whole-liver NHEJ-mediated Pcsk9 editing, with reductions of blood PCSK9 protein levels of more than 90% and of blood cholesterol levels of about 40%, very similar to the effects observed in the aforementioned studies with adenoviral delivery of SpCas9.

The successful use of AAV was followed by the use of nonviral methods to deliver CRISPR/Cas9 into the liver in vivo. In the first study with CRISPR/Cas9 delivered into the liver solely via a nonviral method, lipid nanoparticles (LNP)s formulated either with the SpCas9 mRNA or with a synthesized guide RNA targeting a sequence in Pcsk9 were serially injected into wild-type mice, resulting in reductions of PCSK9 protein levels within the liver by 40%–50% (41). In a subsequent study, LNPs formulated either with the SpCas9 mRNA or with a mix of two synthesized guide RNAs targeting distinct sequences in Pcsk9 — with chemical modifications intended to enhance RNA stability in vivo — were coadministered to wild-type mice (42). LNP treatment yielded more than 80% whole-liver editing of the gene, with the very high editing rate due to extremely efficient NHEJ-mediated deletion between the sites targeted by the two guide RNAs (Figure 1). The editing resulted in absence of detectable blood PCSK9 protein and 35%–40% reductions of blood cholesterol levels. There was
no editing in the lungs or spleen, implying that either the LNPs specifically targeted the liver, or the Pcsk9 locus was accessible to SpCas9 action only in liver cells.

The next set of studies exploited the development of newer types of genome editing, ranging from base editing to epigenomic editing to RNA targeting. Cytosine base editors can directly introduce nonsense mutations into genes via C-to-T changes or G-to-A changes (the latter resulting from C-to-T edits on the antisense strand) in specific codons. An adenovalor vector encoding the cytosine base editor BE3 along with a guide RNA targeting the Pcsk9 tryptophan-159 codon (TGG, for which G-to-A edits of either or both Gs result in a stop codon) was administered to wild-type mice (43). The treatment resulted in about 30% of the Pcsk9 alleles in the liver being edited, mostly into the desired stop codons but with some bystander edits resulting in missense mutations, as well as indel mutations at a rate of 1%-2%. There were corresponding reductions of blood PCSK9 protein levels of about 60% and of blood cholesterol levels of about 30%.

The same Pcsk9 base-editing strategy was used in one of the first demonstrations of fetal genome editing in mice. By analogy to fetal surgery, in which patients with life-threatening anatomical defects are treated while still in the womb, fetal genome editing would be reserved for patients with severe genetic disorders causing damage at the prenatal stage and resulting in high morbidity and mortality after birth. An adenoviral vector expressing the BE3 base editor targeting Pcsk9 was administered to the livers of fetal mice via injection into the vitelline vein, the precursor to the portal vein (44). This prenatal procedure resulted in permanently reduced postnatal blood PCSK9 and cholesterol levels. (Please note that hypercholesterolemia is not a condition that under any circumstances would require prenatal treatment, and the mouse study was performed only as a proof of concept of fetal genome editing. The same study also reported base editing of the Hpd gene, resulting in the successful treatment of hereditary tyrosinemia type I in fetal mice.)

In a demonstration of epigenome editing, catalytically dead SaCas9 was fused to a KRAB repressor domain; the editor and a guide RNA targeting a sequence in the Pcsk9 promoter were encoded in two separate AAV vectors (45). The AAV vectors were coadministered to wild-type mice, resulting in about 50% reductions in hepatic Pcsk9 gene expression and about 80% reductions in blood PCSK9 protein levels, along with corresponding reductions in blood LDL-C levels. Notably, the therapeutic effects weakened over the course of a few months, suggesting that as expression of the epigenome editor waned, so too did the repression of Pcsk9. Another study demonstrated the use of an RNA editor, CasRx (Cas13d), delivered by an AAV vector to knock down Pcsk9 expression (46). As with epigenome editing, the therapeutic effect would be expected to last only as long as the expression of the editor persisted. Both epigenome editing and RNA targeting would likely require repeated administrations of the treatment in order to maintain chronic therapeutic effects, unlike the “one-and-done” effects that are possible with nuclease editing or base editing.

The most recent set of studies have addressed a key step in the translation of therapeutic genome editing to human patients: demonstration of efficacy and safety in nonhuman primates. The first study used meganuclease rather than a CRISPR editor to target the PCSK9 gene (47, 48). The investigators used an AAV vector encoding a meganuclease specific for a sequence in exon 7 of PCSK9 and expressed from a strong liver-specific promoter. When administered to rhesus macaques via intravenous injection at various doses, the highest dose of the AAV vector resulted in 46% whole-liver PCSK9 editing, with corresponding reductions of blood PCSK9 protein levels of 85% and of blood LDL cholesterol levels of 56%. (Lower AAV doses produced substantially lower editing rates.) The reductions persisted for at least 3 years (48).

Despite the success of the meganuclease nonhuman primate study, several aspects of the study that are relevant to clinical translation are noteworthy. First, there was unintended off-target editing. Although the goal was to disrupt the PCSK9 gene via NHEJ, which would result in small indel mutations, in fact the most frequent editing event was integration of AAV vector sequences into the genome at the site of the double-strand break in the PCSK9 gene, with unclear safety consequences. Second, meganuclease treatment resulted in significant off-target mutagenesis at numerous genomic sites both in the monkey livers in vivo and in human hepatocytes in vitro. Third, there were substantial T cell immune responses against both the AAV vector and the meganuclease, resulting in moderate rises in blood transaminase levels in all treated monkeys several weeks after treatment, consistent with immune-mediated hepatocyte death. The rises spontaneously resolved over the course of several weeks to months without any apparent long-term health consequences or attenuation of the PCSK9 editing or of the blood PCSK9 and LDL-C reductions. These issues notwithstanding, this study established the feasibility of “one-and-done” genome editing in primates, with therapeutic effects lasting for several years so far and, likely, for the lifetimes of the treated animals.

In two recent nonhuman primate studies, the two teams of investigators used adenine base editing to knock down PCSK9 in cynomolgus monkeys (49, 50). LNPs encapsulating both an adenine base editor mRNA and a synthetic guide RNA targeting the

---

**Table 1. Genes with reported evidence of efficacy of genome editing in large-animal preclinical studies or in clinical trials**

| Gene   | Disease for which the gene is a therapeutic target | Species | References |
|--------|--------------------------------------------------|---------|------------|
| PCSK9  | Familial hypercholesterolemia                     | Monkeys | 47-50      |
| ANGPTL3| Familial hypercholesterolemia                     | Monkeys | Unpublished, reported at conferences |
| TTR    | Transthyretin amyloidosis                         | Monkeys, humans | 57          |
| DMD    | Duchenne muscular dystrophy                       | Dogs, pigs | 52, 53     |
| KLKB1  | Hereditary angioedema                             | Monkeys | Unpublished, reported at conferences |

---

The next set of studies exploited the development of newer types of genome editing, ranging from base editing to epigenomic editing to RNA targeting. Cytosine base editors can directly introduce nonsense mutations into genes via C-to-T changes or G-to-A changes (the latter resulting from C-to-T edits on the antisense strand) in specific codons. An adenovalor vector encoding the cytosine base editor BE3 along with a guide RNA targeting the Pcsk9 tryptophan-159 codon (TGG, for which G-to-A edits of either or both Gs result in a stop codon) was administered to wild-type mice (43). The treatment resulted in about 30% of the Pcsk9 alleles in the liver being edited, mostly into the desired stop codons but with some bystander edits resulting in missense mutations, as well as indel mutations at a rate of 1%-2%. There were corresponding reductions of blood PCSK9 protein levels of about 60% and of blood cholesterol levels of about 30%.

The same Pcsk9 base-editing strategy was used in one of the first demonstrations of fetal genome editing in mice. By analogy to fetal surgery, in which patients with life-threatening anatomical defects are treated while still in the womb, fetal genome editing would be reserved for patients with severe genetic disorders causing damage at the prenatal stage and resulting in high morbidity and mortality after birth. An adenoviral vector expressing the BE3 base editor targeting Pcsk9 was administered to the livers of fetal mice via injection into the vitelline vein, the precursor to the portal vein (44). This prenatal procedure resulted in permanently reduced postnatal blood PCSK9 and cholesterol levels. (Please note that hypercholesterolemia is not a condition that under any circumstances would require prenatal treatment, and the mouse study was performed only as a proof of concept of fetal genome editing. The same study also reported base editing of the Hpd gene, resulting in the successful treatment of hereditary tyrosinemia type I in fetal mice.)

In a demonstration of epigenome editing, catalytically dead SaCas9 was fused to a KRAB repressor domain; the editor and a guide RNA targeting a sequence in the Pcsk9 promoter were encoded in two separate AAV vectors (45). The AAV vectors were coadministered to wild-type mice, resulting in about 50% reductions in hepatic Pcsk9 gene expression and about 80% reductions in blood PCSK9 protein levels, along with corresponding reductions in blood LDL-C levels. Notably, the therapeutic effects weakened over the course of a few months, suggesting that as expression of the epigenome editor waned, so too did the repression of Pcsk9. Another study demonstrated the use of an RNA editor, CasRx (Cas13d), delivered by an AAV vector to knock down Pcsk9 expression (46). As with epigenome editing, the therapeutic effect would be expected to last only as long as the expression of the editor persisted. Both epigenome editing and RNA targeting would likely require repeated administrations of the treatment in order to maintain chronic therapeutic effects, unlike the “one-and-done” effects that are possible with nuclease editing or base editing.

The most recent set of studies have addressed a key step in the translation of therapeutic genome editing to human patients: demonstration of efficacy and safety in nonhuman primates. The first study used meganuclease rather than a CRISPR editor to target the PCSK9 gene (47, 48). The investigators used an AAV vector encoding a meganuclease specific for a sequence in exon 7 of PCSK9 and expressed from a strong liver-specific promoter. When administered to rhesus macaques via intravenous injection at various doses, the highest dose of the AAV vector resulted in 46% whole-liver PCSK9 editing, with corresponding reductions of blood PCSK9 protein levels of 85% and of blood LDL cholesterol levels of 56%. (Lower AAV doses produced substantially lower editing rates.) The reductions persisted for at least 3 years (48).

Despite the success of the meganuclease nonhuman primate study, several aspects of the study that are relevant to clinical translation are noteworthy. First, there was unintended off-target editing. Although the goal was to disrupt the PCSK9 gene via NHEJ, which would result in small indel mutations, in fact the most frequent editing event was integration of AAV vector sequences into the genome at the site of the double-strand break in the PCSK9 gene, with unclear safety consequences. Second, meganuclease treatment resulted in significant off-target mutagenesis at numerous genomic sites both in the monkey livers in vivo and in human hepatocytes in vitro. Third, there were substantial T cell immune responses against both the AAV vector and the meganuclease, resulting in moderate rises in blood transaminase levels in all treated monkeys several weeks after treatment, consistent with immune-mediated hepatocyte death. The rises spontaneously resolved over the course of several weeks to months without any apparent long-term health consequences or attenuation of the PCSK9 editing or of the blood PCSK9 and LDL-C reductions. These issues notwithstanding, this study established the feasibility of “one-and-done” genome editing in primates, with therapeutic effects lasting for several years so far and, likely, for the lifetimes of the treated animals.

In two recent nonhuman primate studies, the two teams of investigators used adenine base editing to knock down PCSK9 in cynomolgus monkeys (49, 50). LNPs encapsulating both an adenine base editor mRNA and a synthetic guide RNA targeting the
splice donor at the end of PCSK9 exon 1 were used to deliver the editor into the liver. Whereas one study demonstrated relatively modest effects — 26% whole-liver PCSK9 editing, 32% reductions of blood PCSK9 levels, and 14% reductions of blood LDL-C levels at 1 month after treatment (49) — the other study demonstrated larger pharmacodynamic effects more relevant to clinical translation — 66% whole-liver PCSK9 editing, about 90% reductions of blood PCSK9 levels, and about 60% reductions of blood LDL-C levels persisting more than 8 months in an ongoing study (50). These studies contrasted with the aforementioned meganuclease nonhuman primate study in several ways. Since the LNP approach did not use any DNA components, there was no risk of vector sequence integration into the genome, and the use of base editing resulted in a specific base pair change in PCSK9, in contrast to the semi-random indels and AAV vector sequence insertions induced by the meganuclease. With base editing, there was no discernible off-target editing at any of a large number of candidate sites in human hepatocytes, and low-level off-target editing at just a single candidate site in monkey liver, with the off-target editing confined to single–base pair changes (rather than indels). Finally, the LNP treatment resulted in immediate, transient rises in blood transaminase levels that spontaneously resolved in 1 to 2 weeks, with no subsequent transaminitis to suggest a robust immune response — although, notably, repeated administration of LNPs to some of the animals in one of the studies did elicit the development of antibodies against the base editor.

Prospects for translation in the near future

On the strength of all of the aforementioned studies, PCSK9 editing appears to be poised to enter clinical trials for patients with hypercholesterolemia and coronary heart disease. The therapeutic potential for genome editing in cardiovascular diseases and other diseases, of course, extends beyond PCSK9 heart disease (Table 1). Preclinical studies have established the prospects for the treatment of homozygous familial hypercholesterolemia by targeting the ANGPTL3 gene in the liver (51). Although not exclusively cardiovascular diseases, accelerated mortality in patients with Duchenne muscular dystrophy or with Hutchinson-Gilford progeria syndrome is driven by cardiovascular complications arising from the heart or from the vasculature, and preclinical studies have demonstrated amelioration of cardiovascular phenotypes with Cas9 nuclease editing and base editing (52–55).

Most promisingly, a phase I clinical trial in which genome editing is being used to treat transthyretin amyloidosis withpolyneuropathy by targeting the TTR gene (encoding transthyretin, a thyroxine and retinol transport protein) in the liver (56) is already under way. Interim results with single doses of LNPs encapsulating both Cas9 mRNA and a synthetic guide RNA targeting TTR, administered to six patients, demonstrated successful knockdown of blood transthyretin levels by as much as 96% at 1 month after treatment (57). Although the amount of TTR editing and the durability of the therapeutic effect remain to be established, and this clinical trial is focused on the treatment of polyneuropathy, the high degree of transthyretin reduction observed would be predicted to benefit patients suffering from cardiomyopathy caused by transthyretin amyloidosis.

It is likely that clinical trials with genome-editing therapies for other cardiovascular diseases will commence in the near future. Remarkably, almost all of the work forming the basis of these clinical trials has unfolded in just the last decade, and we can undoubtedly expect the next decade to see just as extraordinary a rate of progress of development of genome-editing approaches, to the ultimate benefit of patients everywhere.

Acknowledgments

KM is supported by the Winkelman Family Fund in Cardiovascular Innovation.

Address correspondence to: Kiran Musunuru, University of Pennsylvania, 3400 Civic Center Boulevard, Building 421, 11-104 Smilow Center for Translational Research, Philadelphia, Pennsylvania 19104, USA. Phone: 215.573.4717; Email: kiranmusunuru@gmail.com.

1. Musunuru K. Genome Editing: A Practical Guide to Research and Clinical Applications. Academic Press; 2021.
2. Jinek M, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.
3. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
4. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-826.
5. Cho SW, et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013;31(3):229-232.
6. Hwang WY, et al. Efficient genome editing in zebrafish using a CRISPR/Cas system. Nat Bio-technol. 2011;33(3):227-229.
7. Jinek M, et al. RNA-programmed genome editing in human cells. Elife. 2015;2:e00471.
8. Ding Q, et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 2013;13(2):393-394.
9. Ran FA, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520(7546):186-191.
10. Kleinstiver BP, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481-485.
11. Kleinstiver BP, et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. 2015;33(5):1293-1298.
12. Zetsche B, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759-771.
13. Streckr J, et al. Engineering of CRISPR-Cas12b for human genome editing. Nat Commun. 2019;10(1):212.
14. Liu JY, et al. CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature. 2019;566(7743):218-223.
15. Rouet P, et al. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol. 1994;14(12):8096-8106.
16. Bibikova M, et al. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. 2002;161(1):1169-1175.
17. Bibikova M, et al. Enhancing gene targeting with designed zinc finger nucleases. Science. 2003;300(5620):764.
18. Kleinstiver BP, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490-495.
19. Slawmaker IM, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;353(6268):84-88.
20. Fu Y, et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32(3):279-284.
21. Komor AC, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-424.
22. Koblan LW, et al. Efficient C-G-to-G-C base editors developed using CRISPRi screens, target-
library analysis, and machine learning [published online June 28, 2021]. Nat Biotechnol. https://doi.org/10.1038/s41587-021-00938-z.

23. Gaudelli NM, et al. Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–471.

24. Qi LS, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183.

25. Gilbert LA, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442–451.

26. Gilbert LA, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159(3):647–661.

27. Nuñez JK, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenetic editing. Cell. 2021;184(9):2503–2519.

28. Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–157.

29. Abudayyeh OO, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;551(7685):280–284.

30. Cox DBT, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019–1027.

31. Abudayyeh OO, et al. A cytosine deaminase for programmable single-base RNA editing. Science. 2019;365(6451):382–386.

32. Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.

33. Cohen JC, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272.

34. Rao AS, et al. Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke. Circ Genom Precis Med. 2018;11(7):e002162.

35. Zhao Z, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514–523.

36. Hooper AJ, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445–448.

37. Ding Q, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115(5):488–492.

38. Rashid S, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102(15):5374–5379.

39. Akccakaya P, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature. 2018;561(7723):416–419.

40. Wang X, et al. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo—brief report. Arterioscler Thromb Vasc Biol. 2016;36(9):783–786.

41. Jiang C, et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res. 2017;27(3):440–443.

42. Yin H, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35(12):1179–1187.

43. Chadwick AC, et al. In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing. Arterioscler Thromb Vasc Biol. 2017;37(9):1741–1747.

44. Rossidis AC, et al. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat Med. 2018;24(10):1513–1518.

45. Thakore PI, et al. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat Commun. 2018;9(1):1674.

46. He B, et al. Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver. Protein Cell. 2020;11(7):518–524.

47. Wang L, et al. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nat Biotechnol. 2018;36(8):717–725.

48. Wang L, et al. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol Ther. 2021;29(6):2019–2029.

49. Rothgang T, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39(1):949–957.

50. Musunuru K, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429–434.

51. Chadwick AC, et al. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation. 2018;137(9):975–977.

52. Amoasi L, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362(6410):86–91.

53. Moretti A, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med. 2020;26(2):207–214.

54. Chemello F, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv. 2021;7(18):eabg4910.

55. Koblan LW, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021;589(7859):608–614.

56. Finn JD, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227–2235.

57. Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502.

58. Musunuru K. Genome editing: the recent history and perspective in cardiovascular diseases. J Am Coll Cardiol. 2017;70(22):2808–2821.